Heat shock factor (HSF) inhibitor (IC50 = 1.2 μM). Increases apoptosis in cancer cells treated with the HSP90 inhibitors Geldanamycin (Cat. No. 1368) and 17-AAG (Cat. No. 1515). Blocks downstream induction of HSP27 and HSP70. Inhibits tumor growth in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 284.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.52 mL||17.59 mL||35.18 mL|
|5 mM||0.7 mL||3.52 mL||7.04 mL|
|10 mM||0.35 mL||1.76 mL||3.52 mL|
|50 mM||0.07 mL||0.35 mL||0.7 mL|
References are publications that support the products' biological activity.
Yoon et al (2011) KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J.Biol.Chem. 286 1737 PMID: 21078672
Samarasinghe et al (2014) Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux. Biochem. Pharmacol. 87 445 PMID: 24291777
If you know of a relevant reference for KRIBB11, please let us know.
View Related Products by Target
Keywords: KRIBB11, supplier, HSF1, inhibitors, inhibits, heat, shock, factors, 1, HSP90, HSP70, HSP27, proteins, Hsp90, Hsp70, Other, Transcription, Factors, Hsp90, Tocris Bioscience
Citations for KRIBB11
Citations are publications that use Tocris products.
Currently there are no citations for KRIBB11. Do you know of a great paper that uses KRIBB11 from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.